Article info
PDFLaw, ethics and medicine
Ethical issues in psychopharmacology
- Correspondence to: Leemon McHenry California State University, Northridge, Department of Philosophy, 18111 Nordhoff Street, Northridge, California 91330-8253, USA; lmchenry{at}earthlink.net
Citation
Ethical issues in psychopharmacology
Publication history
- Received June 15, 2005
- Accepted September 30, 2005
- Revised September 29, 2005
- First published June 30, 2006.
Online issue publication
April 27, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2006 by the Journal of Medical Ethics
Other content recommended for you
- Observing time effect of SSRIs on suicide risk and suicide-related behaviour: a network meta-analysis protocol
- Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials
- Suicide-related events in young people following prescription of SSRIs and other antidepressants: a self-controlled case series analysis
- SSRI use and risk of fractures among perimenopausal women without mental disorders
- Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review
- Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports
- The trouble with antidepressants: why the evidence overplays benefits and underplays risks—an essay by John B Warren
- Antidepressant use and risk of adverse outcomes in older people: population based cohort study
- Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants
- Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration